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A  ﬁrst-generation  oral  inactivated  whole-cell  enterotoxigenic  Escherichia  coli  (ETEC)  vaccine,  compris-
ing  formalin-killed  ETEC  bacteria  expressing  different  colonization  factor  (CF)  antigens  combined  with
cholera  toxin  B subunit  (CTB),  when  tested  in phase  III studies  did  not  signiﬁcantly  reduce  overall  (gen-
erally mild)  ETEC  diarrhea  in travelers  or children  although  it reduced  more  severe  ETEC  diarrhea  in
travelers  by almost  80%.  We  have  now  developed  a novel  more  immunogenic  ETEC  vaccine  based  on
recombinant  non-toxigenic  E.  coli strains  engineered  to express  increased  amounts  of CF  antigens,  includ-
ing CS6  as  well  as  an  ETEC-based  B  subunit  protein  (LCTBA),  and  the  optional  combination  with  a  nontoxic
double-mutant  heat-labile  toxin  (LT) molecule  (dmLT)  as  an  adjuvant.
Two test  vaccines  were  prepared  under  GMP:  (1)  A prototype  E. coli CFA/I-only  formalin-killed  whole-
cell  +  LCTBA  vaccine,  and  (2)  A “complete”  inactivated  multivalent  ETEC-CF  (CFA/I, CS3,  CS5  and  CS6mmune responses
ucosal immunity
antigens)  whole-cell  + LCTBA  vaccine.  These  vaccines,  when  given  intragastrically  alone  or  together  with
dmLT  in  mice,  were  well  tolerated  and  induced  strong  intestinal-mucosal  IgA  antibody  responses  as
well  as serum  IgG and  IgA  responses  to each  of  the  vaccine  CF  antigens  as well  as  to  LT  B  subunit
(LTB).  Both  mucosal  and serum  responses  were  further  enhanced  (adjuvanted)  when  the  vaccines  were
co-administered  with  dmLT.  We  conclude  that  the  new  multivalent  oral  ETEC  vaccine,  both  alone  and
especially  in  combination  with  the  dmLT  adjuvant,  shows  great promise  for  further  testing  in humans.. IntroductionETEC is the most common cause of bacterial diarrhea both
mong children in developing countries and in travelers to these
Abbreviations: CF, colonization factor; CT, cholera toxin B subunit; CTB, cholera
oxin binding subunit; dmLT, double-mutant LT; ELISA, enzyme linked immunosor-
ent assay; ETEC, enterotoxigenic Eschericia coli; EV, ETEC vaccine; GMP, good
anufacturing practice; i.g. immunization, intragastric immunization; LT, heat
abile toxin; LTB, heat labile toxin binding subunit; PV, prototype vaccine.
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regions [1]. ETEC causes disease by colonizing the small intestine
by means of “colonization factors” (CFs), most of which are ﬁmbriae
[2], and by producing a cholera toxin (CT)-like heat-labile toxin (LT)
and/or a non-immunogenic polypeptide heat-stable enterotoxin
(ST). Both naturally acquired infection and oral-mucosal vaccina-
tion against LT or various CFs can induce protective immunity,
and in animal models anti-LT and anti-CF antibodies cooperate to
exhibit a synergistic protective effect [3–5].
There is a great need for an effective vaccine against ETEC for use
both in children living in ETEC-endemic countries and in travelers.
The serological diversity of ETEC with more than 100 O groups [6]
and many different CFs [2] represents a great problem for vaccine
development. However, several vaccine candidates mainly for oral
Open access under CC BY-NC-ND license.administration and consisting of toxin-derived antigens alone or
together with CF antigens, either puriﬁed or expressed on the bac-
terial surface, have been developed. These vaccines are in different
stages of testing, and one vaccine, the oral cholera vaccine Dukoral
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s licensed in some countries for use also against ETEC in travelers
ased on its short-term cross-protective effect against LT-mediated
TEC diarrhea [3,7,8].
We  have earlier developed an oral ETEC vaccine consisting of
ormalin-inactivated ETEC bacteria expressing various prevalent
Fs and recombinantly produced CTB (rCTB) [9,10]. This vaccine,
iven in a two- or three-dose regimen, was safe and induced
ntestinal-mucosal immune responses in 70–90% of Swedish,
angladeshi and Egyptian vaccinees of different ages. However,
hen tested in phase III studies it did not signiﬁcantly reduce over-
ll (usually mild) ETEC diarrhea in travelers or children although it
educed more severe ETEC diarrhea in travelers by almost 80% [11].
t was also found that in infants 6–17 months of age a full dose
f vaccine (but not a quarter-dose) induced with some frequency
omiting that would affect acceptability of the vaccine for use in
nfants [12].
We now describe the development and preclinical testing of a
nd generation oral ETEC vaccine. The aim has been to improve
he immunogenicity of the vaccine without increasing the dosage
and for the youngest age group hopefully being able to reduce
t) by introducing several improvements compared to the 1st
eneration vaccine: (1) Use E. coli strains engineered to express
ncreased amounts of CF antigens [13–15]; (2) Replace rCTB with a
TB/LTB hybrid B subunit protein (LCTBA) inducing a stronger anti-
T immune response [16]; (3) Optionally add a promising combined
ucosal adjuvant and LT antigen, such as dmLT [17]. Increasing
he CF antigen content per dose and evaluating the impact of
dding a mucosal adjuvant to the vaccine formulation were also
HO’s recommendations for improving this vaccine concept [18].
s described here, based on these principles we have prepared
wo ETEC vaccines under GMP  and tested them preclinically: a
rototype vaccine (PV) consisting of E. coli CFA/I-only formalin-
illed bacteria + LCTBA, and a “complete” multivalent ETEC vaccine
EV) containing a cocktail of four inactivated recombinant E. coli
trains expressing increased amounts respectively of CFA/I, CS3,
S5 and CS6 antigens in combination with the LCTBA protein. When
ested in mice, oral immunizations with these strains individu-
lly have induced signiﬁcantly higher intestinal as well as serum
ntibody responses against the various CFs than achieved with cor-
esponding 1st generation vaccine strains [19]. Now, these vaccines
iven alone or together with dmLT, were tested in mice after oral
mmunizations for potential adverse reactions and stimulation of
erum IgG and IgA and intestinal-mucosal IgA antibody responses
o the different vaccine components. The results show that: (1) Both
accines, also with dmLT, were well tolerated; (2) Both vaccines
nduced strong serum as well as intestinal antibody responses to
ach of the CF antigens included in the vaccines and to LT; and (3)
he dmLT adjuvant signiﬁcantly enhanced especially the intestinal
mmune responses to the various vaccine components.
. Materials and methods
.1. Vaccines and adjuvants
Two vaccines prepared under GMP  were tested alone and
ogether with GMP  dmLT or with CT as adjuvants: (1) A
onovalent prototype vaccine (PV) consisting of formalin-killed
FA/I-overexpressing E. coli + LCTBA, which has now also been eval-
ated in humans for its safety and immunogenicity [20] and (2)
 multivalent CF-whole-cell + LCTBA ETEC vaccine (EV) containing
our inactivated E. coli strains recombinantly expressing increased
mounts respectively of CFA/I, CS3, CS5 and CS6 antigens mixed
ith the LCTBA protein. The preparation and characterization of
accines and dmLT are described in the Appendix; CT was  pur-
hased from List Biological Laboratories (Campbell, CA, USA).1 (2013) 2457– 2464
2.2. Immunizations and sample collections
Female BALB/c and for EV also C57/Bl6 (B6)mice (Charles
River; 6–8 weeks of age; 5–10 mice/group) were used for
“oral”/intragastric (i.g.) immunizations. When not otherwise spec-
iﬁed, three rounds of immunization were given at 12–15 days
intervals, each comprising two or three i.g. administrations on con-
secutive days of one-half or one-third of the total dose in 0.3 ml  3%
(w/v) sodium bicarbonate through a baby feeding catheter; food
was removed for 2–3 h before each administration. Unless speciﬁed
differently, total vaccine doses in each round were for PV 4 × 108
inactivated bacteria (containing 8 g CFA/I) + 13 g LCTBA, given
alone or with 15 g CT or 25 g dmLT, and for EV 1 × 109 inactiv-
ated bacteria (containing 10 g CFA/I, 38 g CS3, 6.4 g CS5 and
1.5 g CS6) + 13 g LCTBA alone or together with 25 g dmLT.
Bleedings were performed before the ﬁrst, and one day before
and 10–12 days after the last round of immunization, when fecal
pellets were also collected and extracts prepared as described [21].
At the last time point when animals were sacriﬁced, and in a subset
of mice sacriﬁced 11–12 days after the 2nd immunization round,
the mice were perfused with a heparin-PBS solution to remove
blood from the tissues, and jejunal tissue collected and extracted
with a 2% Saponin-PBS solution (the Perfext method) [22]. Fecal
and jejunal tissue extracts from unimmunized mice (“Nil”) served
as controls.
2.3. Immunological assays
IgA and IgG antibodies against CFA/I, CS3, CS5, CS6 and LTB in
serum, and IgA antibodies to the same antigens in fecal and jeju-
nal extracts were determined by ELISA; in fecal and jejunal extract
samples total IgA was also measured by ELISA [14,15,23]. Antibody
titers were estimated as the reciprocals of the extrapolated sample
dilutions giving absorbance (A450) of 0.4 above background, and for
fecal and jejunal samples these titers were adjusted to the total IgA
contents [19] and expressed as ELISA units [EU] per g of total IgA.
All antibody levels were log10 transformed; the log-transformed
values were used for graphs and statistical analyses.
2.4. Statistical analyses
Statistical analyses between groups were conducted by Stu-
dent’s two-tailed t-test, with P values of <0.05 regarded as
signiﬁcant.
3. Results
3.1. Vaccines are stable and safe also with adjuvants
As further described in the Appendix, repeated dose toxicity
studies in mice of PV, EV and EV mixed with dmLT, in dosages corre-
sponding on a weight basis to up to 100 times the intended human
dose were undertaken. All preparations were judged to be very well
tolerated and safe for clinical studies in humans. This was further
conﬁrmed in the immunization experiments described below in
which PV and EV, alone or with dmLT, were tested at even higher
dosages and continued to be well tolerated.
As also further described in the Appendix, stability testing of
stored PV, EV and their monovalent whole-cell bulk and LCTBA
preparations as well as of dmLT has not indicated any product
changes after 18–46 months surveillance of the various compo-
nents.
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Fig. 1. Oral-i.g. immunization of mice with PV induces strong intestinal IgA and serum IgG and IgA antibody responses to CFA/I that are further increased when immunizations
are  performed with PV co-administered with dmLT or CT adjuvants: (A) Fecal IgA anti-CFA/I responses to three rounds of i.g. immunization with different dosages of PV
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C4  × 108 inactivated bacteria/13-g LCTBA [PV] and 5-fold [PV:5] or 25-fold [PV:25
V  bacterial component without any LCTBA, and Nil represents fecal extracts from 
gG,  and (D) IgA anti-CFA/I antibody responses. Student’s two-tailed t-tests were do
5–6  animals per group). The results are from one of three experiments giving simi
.2. Oral immunization with PV elicits intestinal and serum
ntibody responses that are further adjuvanted by dmLT
Initial immunization studies were performed with the CFA/I-
. coli + LCTBA prototype vaccine (PV) tested in different dosages
lone and with CT or dmLT as adjuvants.
Anti-CFA/I responses. As shown in Fig. 1A i.g. immunization with
V induced a dose-related fecal anti-CFA/I IgA antibody response,
or the highest PV dose resulting in a 70-fold antibody rise com-
ared to unimmunized controls. Co-administration with dmLT, to
he same extent as with CT, further enhanced this response. Sim-
lar effects were seen in jejunal tissue extracts (Fig. 1B). Likewise,
he immunizations with PV induced substantial IgG as well as IgA
nti-CFA/I serum antibody responses which were further signiﬁ-
antly and similarly enhanced by co-administration with dmLT or
T (Fig. 1C and D).ions thereof) given alone or with 15 g CT or 25 g dmLT; PV bulk represents the
unized mice. (B) Anti-CFA/I IgA antibody responses in jejunal extracts. (C) Serum
en testing signiﬁcances in antibody levels between indicated immunization groups
ults.
Anti-LTB immune responses. The intestinal-mucosal and serum
antibody responses to LTB were also examined. Immunization with
the highest PV dose induced signiﬁcant intestinal as well as serum
anti-LTB antibody levels compared to controls, which were much
further enhanced by co-administration with either CT or dmLT
(Fig. 2). Since the latter increases could have been due to the
increased amounts of LTB antigen provided by the addition of dmLT,
we tested in a separate experiment anti-LTB as well as anti-CFA/I
responses after similar immunizations with PV + 25 g rCTB and
found that the responses then achieved were similar to those after
immunization with PV alone and much lower than after immuniza-
tion with PV + dmLT (not shown). We  also tested the adjuvant effect
of lower doses of dmLT and found that when added to PV 10- or 5-
g dmLT doses were only slightly inferior to the standard 25-g
dose, whereas a 2.5-g dose had no signiﬁcant adjuvant effect on
either the anti-CFA/I or anti-LTB responses (not shown).
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Fig. 2. Oral-i.g. immunization of mice with PV also induces strong intestinal IgA and serum IgG and IgA antibody responses to LTB that are further enhanced by co-
administration with CT or dmLT. Immunizations and samples examined are the same as described in Fig. 1. Bars show the indicated anti-LTB antibody levels after immunization
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ere  done to test signiﬁcances in antibody levels between indicated immunization
.3. Oral immunization with EV induces strong intestinal and
erum antibody responses to all vaccine components that are
urther increased by dmLT
We undertook similar immunogenicity studies with the GMP-
repared multivalent CF-ETEC whole-cell + LCTBA vaccine (EV)
lone and together with the GMP-prepared dmLT; we tested
esponses in both Balb/c and C57/Bl6 mice since we had previ-
usly found [15] stronger immune responses to the CS6 antigen
n C57/Bl6 than in Balb/c mice.
Studies of fecal IgA antibody responses showed that the vaccine
y itself induced signiﬁcant 3-to 25-fold titer rises to each of the
FA/I, CS3, CS5, CS6 and LTB antigens in the vaccine, which were
urther signiﬁcantly increased 3- to 100-fold by giving the vaccine
ogether with dmLT (Fig. 3A). The IgA antibody responses in jejeunal
xtracts showed a similar picture (Fig. 3B). Conﬁrming our previous
eport [15], we saw a stronger anti-CS6 response in C57/Bl6 com-
ared to Balb/c mice in jejunal extracts and in serum (see below);
his differed from the responses to the other vaccine antigens which
ere equal or slightly higher in the Balb/c mice (data not shown).
Analyses of serum antibodies also demonstrated strong IgG
Fig. 3C) as well as IgA (Fig. 3D) antibody responses to each of
he vaccine antigens already after immunization with EV alone.
mmunization together with dmLT tended to further enhance
hese responses, but to a lesser extent than for the fecal and
ejunal responses and statistically signiﬁcant only for serum IgA
esponses to CS3 and CS6 (in C57/Bl6 mice) and IgG and IgA anti-LTB
esponses.We also compared the intestinal and serum antibody responses
fter two rounds of i.g. immunizations with those described after
hree immunization rounds. As seen in Table 1, substantial fecal,
ejunal and serum antibody responses to all antigens were achievedmunized controls or for serum preimmunization titers. Student’s two-tailed t tests
s. The results are from one of three experiments giving similar results.
already after two rounds of immunization, both with EV alone and
even stronger with EV + dmLT. In general, the fold-increase rises in
antibody titer were lower after two  as compared to three rounds
of immunization (Table 1).
4. Discussion
By constructing plasmids in which the genes for the different
CF antigens were placed behind strong promotors, and incorpo-
rating these plasmids in E. coli K12 or a toxin-negative O78 ETEC
strain, recombinant vaccine strains were engineered that expressed
4- to 10-fold higher levels of CFA/I and CS1-CS5 compared to the
strains used in the 1st generation ETEC vaccine [19]. In addition,
we engineered a novel vaccine strain producing a high level of CS6
[15], an antigen which is increasingly prevalent on clinical ETEC
isolates [24,25] and was practically lacking in the previous vac-
cine. Likewise, immunization with the engineered LCTBA protein
(a hybrid CTB/LTB molecule [16]) has induced a stronger anti-LTB
response including stronger LT-neutralizing activity than achieved
with the rCTB component of the 1st generation vaccine [16; N. Car-
lin et al. unpublished data]. Based on this, we  describe here the
development and preclinical evaluation of a new oral ETEC vac-
cine (EV) containing a cocktail of four inactivated recombinant
E. coli strains expressing increased amounts of CFA/I, CS3, CS5 and
CS6 antigens mixed with the LCTBA protein. This vaccine, whose
composition makes it substantially more immunogenic than the
previously tested vaccine, was prepared under GMP, as was  also an
earlier monovalent prototype vaccine (PV) containing only CFA/I-
overexpressing inactivated bacteria together with LCTBA [20].
As described, ﬁrst PV and then EV were tested in mice after oral
immunizations for their safety and capacity to induce intestinal IgA
and serum IgG and IgA antibody responses to the different vaccine
J. Holmgren et al. / Vaccine 31 (2013) 2457– 2464 2461
Fig. 3. Oral immunization with EV induces strong intestinal and serum antibody responses to all vaccine components that are further adjuvanted by dmLT. After three rounds
of  i.g. immunizations with EV alone, EV together with 25 g dmLT or only bicarbonate buffer (Nil) IgA antibodies to CFA/I, CS3, CS5, CS6 and LTB were measured in (A) fecal
extracts or (B) jejunal tissue extracts, and IgG and IgA antibodies to these antigens were also determined in serum (C). Results show antibody responses in Balb/c mice and
for  anti-CS6 also in C57/Bl6 mice (hatched bars). Student’s two-tailed t-tests were done to test signiﬁcances in antibody levels between indicated immunization groups; for
serum  samples *, ** and *** represent p values of <0.05, <0.01 and 0.001, respectively. Results shown are from one of two independent experiments giving closely similar
results.
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Table  1
Comparisons of fold-increase responses to different vaccine components after two versus three rounds of oral immunization with EV or EV + dmLT.a
Immunization a-CFAI a-CS3 a-CS5 a-CS6 (B6) a-LTB
2 3 2 3 2 3 2 3 2 3
Fecal IgA EV 12 20 9 13 20 100 8
(25)
3
(5)
2 3
EV  + dmLT 63 200 50 200 25 300 30
(4)
25
(25)
250 630
Jejunal IgA EV 3 30 11 63 16 50 1
(3)
1
(6)
1 7
EV  + dmLT 8 63 35 112 30 80 2
(16)
2
(50)
11 56
Serum IgA EV 50 100 10 80 25 60 2
(2)
2
(3)
6 11
EV  + dmLT 100 250 60 250 80 150 2
(4)
4
(40)
200 8000
Serum IgG EV 250 400 25 500 50 400 5
(40)
15
(500)
6 60
EV  + dmLT 400 400 500 1400 100 800 13
(16)
160
(600)
110 4000
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Aa Values given are geometric mean fold-increase antibody levels over correspon
ssays) in Balb/c mice; for antibodies to CS6 corresponding fold-increases in C57/Bl
omponents. An important study objective was also to determine
hether co-administration of the vaccines with the mucosal adju-
ant dmLT [17] could further enhance these immune responses
ithout jeopardizing vaccine safety. On a per body-weight basis
he dosages used were for PV 10–15 times the prospected human
dult dose of the bacterial component and 30–50 times of LCTBA,
nd for EV 30–50 times the human dose of both inactivated bacte-
ia and LCTBA. The dmLT adjuvant dose used in the mice would
orrespond to more than 1000 times a prospected human dose of
0–25 g. The results show that both PV and EV, whether given
lone or with dmLT, were extremely well tolerated, which was
onﬁrmed in extended toxicity studies according to European Phar-
acopea recommendations for biological products in which PV and
V ± dmLT were tested in repeated doses up to 100 (PV) and 25
imes (EV) the prospected human dose and found to be safe.
Oral immunizations with both PV and EV induced signiﬁcant,
sually strong serum IgG and IgA as well as intestinal IgA antibody
esponses to each of the CF antigens in the vaccines and also to
TB even when the vaccines were administered without any adju-
ant. The strong IgA antibody responses in fecal and jejunal extracts
re of special importance since they probably best reﬂect the pro-
ective efﬁcacy of the vaccines [5,26]. Several previous studies have
emonstrated a close correlation between IgA antibody levels mea-
ured in fecal and jejunal extracts [14,15,21], which was also seen
n this study, and have also shown that the levels of IgA antibod-
es in jejunal extracts from perfused animals induced by the PV or
V vaccines, when compared to the IgA antibody levels in serum,
re much too high to represent transudation from blood [26,27].
e are therefore conﬁdent that the IgA antibodies to the various
accine components in fecal and jejunal extracts measured after
.g. immunizations with PV or EV largely, if not exclusively, reﬂect
ocally produced mucosal antibodies.
Of great potential importance for the further develop-
ent and clinical testing of EV and other oral ETEC vaccines,
o-administration of both PV and EV with dmLT adjuvant signif-
cantly enhanced especially the intestinal IgA responses to the
arious vaccine components. The dmLT is a genetically engineered
T protein containing two genetic substitutions (R192G/L211A) in
he A subunit which appear to completely eliminate the enterotoxic
ctivity of the parent LT without removing the adjuvant activity
17]. Several studies have shown that dmLT can function as a strong,
nd apparently non-toxic, adjuvant for stimulating both B and T cell
mmune responses in mice to various vaccine antigens [17,28,29].
 recent study has also demonstrated that at least 100 g of dmLTevels before immunization (serum) or in unimmunized controls (fecal and jejunal
 mice are also shown in parentheses.
could be given orally to humans without causing adverse reactions
(L Bourgeois, personal communication). In the present study we
show that when added to PV dmLT is similarly effective as the “gold
standard” adjuvant CT in promoting both anti-CFA/I and anti-LTB
antibodies. When different dosages of vaccine (PV) were tested, the
adjuvant effect of dmLT appeared especially strong for the lower
vaccine dosages. This suggests the potential for vaccine dose spar-
ing when an effective adjuvant is added, which could be of special
value for use of ETEC vaccines in younger age groups in which lower
than adult vaccine doses may  be needed. Since the increase in anti-
LTB antibodies could have been explained by the increased amounts
of LT-related antigen provided through the added dmLT rather than
by a true adjuvant effect, we also tested the anti-LTB and anti-CFA/I
responses after similar immunizations with PV together with 25 g
rCTB. These responses were much lower than after immunization
with PV + dmLT and similar to those after immunization with PV
alone, thus supporting the mucosal adjuvant activity of dmLT for
both antibacterial and antitoxic immunity. The potency of dmLT
as an adjuvant for both types of antibody responses was further
underlined in the immunization studies with EV, where dmLT sig-
niﬁcantly enhanced the IgA mucosal immune responses to each
of the four CF antigens as well as to LTB. Studies in progress will
determine if the adjuvant also adds to the duration of these
responses and/or to immunologic memory for later boosting. Also
serum IgG and IgA antibody responses were enhanced by dmLT, but
to a lesser extent than the intestinal-mucosal IgA responses. The
latter may  be explained by the already quite high serum antibody
levels achieved with EV alone; it could also be that the adjuvant
activity of dmLT in a more speciﬁc way promotes mucosal IgA
responses.
We conclude that the described novel oral inactivated whole-
cell/B subunit ETEC vaccines, containing inactivated E. coli strains
overexpressing different CF antigens and the LCTBA B-subunit
protein, have excellent safety and immunogenicity when tested
in mice, and that especially the intestinal-mucosal IgA antibody
responses are substantially increased even further by the dmLT
adjuvant. Based on these results and those from a just completed
study in humans with PV (without adjuvant) [20], phase I studies in
adult Swedish volunteers are now under way to assess the reacto-
genicity and immunogenicity after two oral immunizations with EV
alone and together with different doses of dmLT. Pending favorable
results from that trial, we  plan to proceed with extended immu-
nization studies in adults, toddlers and infants in an ETEC-endemic
setting.
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ppendix A.
.1. Preparation of vaccines
Monovalent CFA/I-ETEC/LCTBA prototype vaccine (PV). A CFA/I-
verexpressing E. coli strain (V109) was generated with the aid of
n expression plasmid containing the CFA/I operon under a strong
ac promoter and a non-antibiotic selection marker, thyA, originat-
ng from Vibrio cholerae [13,19]. The plasmid was inserted into a
ost E. coli K12 strain (C600) whose chromosomal thyA gene had
een deleted, thus allowing antibiotic free selection of plasmid-
ontaining organisms by culturing the strain in thymine-deﬁcient
ubstrate. In non-GMP laboratory scale studies, the V109 strain
xpressed 5–15-fold more CFA/I than the reference 1st generation
TEC vaccine CFA/I strain as determined by an antigen-speciﬁc inhi-
ition enzyme-linked immunosorbent assay (ELISA) [13]. When
repared under GMP, after growth of the strain V109 in CFA
edium [30] in a 500-l fermentor at 37 ◦C for 6–8 h in presence of
 mM IPTG, followed by extensive washing and inactivation with
ormalin [19] and renewed extensive washing, the ﬁnal PV con-
ained 600 g CFA/I per human dose, 3-fold more than the reference
accine.
LCTBA is a hybrid protein between LTB and CTB, in which seven
mino acids in CTB have been replaced by corresponding amino
cids of LTB [16]. This makes the LCTBA molecule closely similar
o LTB with regard to immunogenicity including the generation
f LT-neutralizing antibodies [16]. Puriﬁed LCTBA was prepared
s described [20] under GMP  from the culture medium of a
ontoxigenic V. cholerae production strain harboring a multicopy
xpression plasmid and grown in a 500-l fermentor.
The ﬁnal GMP-prepared PV contained 3 × 1010 formalin-
nactivated CFA/I- E. coli bacteria (strain V109) mixed with 1.0 mg
CTBA in 6 ml  saline (dispensed in glass vials representing one
uman dose).
Multivalent ETEC-CF/LCTBA vaccine (EV). A “complete” multiva-
ent ETEC-CF/LCTBA vaccine (EV) was developed consisting of four
nactivated recombinant E. coli strains (ETEX21-24) engineered to
verexpress CFA/I, CS3, CS5, and CS6, respectively, mixed with
CTBA. Similar to the PV strain, these strains have in common that
he CF antigens are expressed under a strong promoter from plas-
ids, modiﬁed to also harbor the thyA gene, and placed in host E. coli
trains whose own chromosomal thyA gene has been deleted.
The vaccine strains producing CFA/I, CS3 or CS5 were inactivated
ith formalin [19]. The CS6-producing strain was  instead inactiv-
ted with phenol since we have found that formalin but not phenol
estroys the CS6 protein on the bacterial surface [15,31]. Individ-
al inactivated vaccine bulks were then aseptically mixed with each
ther and with the LCTBA protein (the same preparation as used in1 (2013) 2457– 2464 2463
PV) to yield a ﬁnal EV with the following composition per planned
human dose: ETEX21, 830 g CFA/I on 2 × 1010 bacteria; ETEX22,
2970 g CS3 on 2 × 1010 bacteria; ETEX23, 510 g CS5 on 2 × 1010
bacteria; ETEX24, 120 g CS6 on 2 × 1010 bacteria; LCTBA 1.0 mg;
Phosphate-buffered saline q.s. ad 8 ml.  These CF antigen levels are
much higher than in the 1st generation ETEC vaccine, which per
2,5 × 1010 bacteria contained 150–200 g of CFA/I, CS3 and CS5 and
<5 g CS6.
Strain ETEX21 overexpressing CFA/I was developed using a recom-
binant plasmid expressing the CFA/I operon under tac promoter
and also equipped with a thyA gene as described above for PV.
Compared to PV, the host strain was an E. coli CFA/I (O78:K-,ST)
which was  originally isolated from a patient with watery diar-
rhea in Dhaka, Bangladesh, from which the plasmid(s) encoding
the ST and CFA/I native genes were removed by natural selection
[32]. Further modiﬁcation was done by inactivating the thyA gene
on the chromosome through insertion of a kanamycin resistance
gene in the thyA gene. In a second round of chromosomal deletion,
the kanamycin gene was then deleted of its ﬁrst 200 nucleotides
together with 200 nucleotides from the thyA gene making the strain
kanamycin sensitive.
Strain ETEX22 overexpressing CS3 was  developed using a recom-
binant plasmid expressing the entire CS3 operon under the rns
promoter which in turn is under the lac operator. The bacterial
host for this construct was the same E. coli O78:K- strain that was
used for ETEX21. By similar steps as described for ETEX21, the non-
antibiotic selection marker thyA was  used to provide antibiotic free
selection of plasmid-expressing organisms.
Strain ETEX23 overexpressing CS5 was  developed using a recom-
binant plasmid expressing the entire CS5 operon under tac
promotor, also harboring thyA as a non-antibiotic selection marker.
The bacterial host for this construct is the same E. coli O78:K- strain
used for ETEX 21 and ETEX 22.
E. coli strain ETEX24 overexpressing CS6 was  developed using a
recombinant plasmid expressing the entire CS6 operon under tac
promotor. The bacterial host for this construct was  the same mod-
iﬁed E. coli K12 strain C600 as used in the PV.
After growth of each strain in a 500-liter fermentor at 37 ◦C for
6–8 h following IPTG induction, in CFA medium [30] for ETEX21,
22 and 24 and in modiﬁed Syncase medium [33] for ETEX23, the
bacteria were inactivated, for ETEX21, 22 and 23 using formalin as
described [19], and for ETEX24 instead using phenol [15] since it
was found that phenol in contrast to formalin preserves the CS6
antigen on the bacterial surface [15].
Both PV and EV were prepared under GMP  at Unitech Biopharma
AB, Matfors, Sweden.
A.2. Preparation of dmLT adjuvant
The dmLT (R192G/L211A) adjuvant is based on two genetic
substitutions in the A subunit (R192G/L211A) which apparently
completely eliminates the enterotoxic activity of the parent LT
without removing the adjuvant activity [17]. Initially, a single-
mutant LT (“mLT,” LT[R192G]) was constructed by substitution of
arginine with glycine at position 192 of the A subunit. This genetic
modiﬁcation eliminated the ability of subunit A to be activated by
trypsin cleavage and greatly reduced the enzymatic and biological
activity of the toxin [34]. Further attenuation was accomplished
by adding a second substitution, leucine to alanine at position 211
[17]. The double mutant LT (dmLT; R192G/L211A) has less than 0.1%
of the enzymatic activity (ADP-ribosylation) of LT and induced no
detectible ﬂuid accumulation when given to mice by the intragas-
tric route, while retaining immunogenicity and adjuvanticity [17].
The preparations used were produced and puriﬁed as described
[17]; the lot used with EV was prepared under GMP  at the Walter
Reed Army Institute of Research Pilot Bioproduction Facility, Silver
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pring, MD,  USA. Lyophilized dmLT preparations were diluted and
tored at 1 mg/ml  at 4 ◦C until mixed with PV or EV for the studies
escribed.
.3. Antigens for immunological assays
Puriﬁed CFA/I, CS3, and CS5 antigens were prepared as described
21,32, Unpublished data]. Puriﬁed CS6 antigen [35] was  a kind gift
rom Dr F Cassel. LTB was prepared by Etvax AB from a recombi-
ant plasmid expressed and puriﬁed in a manner similar to that
f LCTBA. All antigens gave a single band in SDS gel electrophore-
is and when tested in ELISA reacted speciﬁcally with matching
onoclonal antibodies [23,31] but not with anti-O78 monoclonal
ntibody or hyperimmune sera against any of the host strains used
n the PV or EV vaccines. Immunological speciﬁcity was further
ocumented by ELISA studies showing that mouse antisera raised
gainst individual CF-overexpressing E. coli strains reacted with the
ppropriate but not with any other CF antigen.
.4. Stability and toxicology studies of vaccines
Monovalent PV and EV bulk preparations and LCTBA, as well as
he ﬁnal PV and EV vaccines stored at 4 ◦C and 25 ◦C are subjected
o an ongoing 48-months ICH compliant stability study. Similarly,
MP-made dmLT in lyophilized vials stored at −20 ◦C is being
ested in an ongoing 36-months stability study. No signs of prod-
ct changes have been found to date (15–43 months for various
omponents).
Repeated dose toxicity studies of both PV, EV, and EV with dmLT,
n doses corresponding to up to 100 times the intended human
ose on a weight basis were conducted in mice by Visionar AB,
ppsala, Sweden in accordance with European Pharmacopea GLP
tudy criteria for biological products. Both when tested alone and
ogether with dmLT, the vaccines were judged to be very well
olerated and safe for clinical studies in humans. No deaths or histo-
ogical changes were found, and only at the highest dosages tested a
ew animals showed mild transient weight loss and/or a few minor
iochemistry changes were recorded.
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